Sucampo Pharmaceuticals, Inc. : Sucampo Appoints Silvia Taylor, MBA, as Senior Vice President, Investor Relations, Public Relations, and Corporate Communications
06/28/2012| 12:10pm US/Eastern
Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that Silvia Taylor
has joined the company as Senior Vice President of Investor Relations,
Public Relations, and Corporate Communications, reporting to Cary J.
Claiborne, Chief Financial Officer. She will lead Sucampo's investor
relations, public relations, media relations and internal communications
efforts with responsibility to establish the corporate brand, and to
enhance Sucampo's presence among the investment audience and other
stakeholder groups as well as in the different communities in which the
company operates globally.
Silvia Taylor, Senior Vice President of Investor Relations, Public Relations, and Corporate Communications (Photo: Financial Communications Inc.)
Ryuji Ueno, M.D., Ph.D., Ph.D., Chair of the Board, CEO and CSO, said,
"Ms. Taylor brings extensive experience in large and mid-size public
biopharmaceutical companies, and we look forward to her leadership in
defining our corporate brand and overarching communications strategy
among all of our corporate and product-related audiences. She will build
upon the corporate awareness campaign we started earlier this month to
increase awareness of Sucampo and our proprietary prostone technology.
And, as a science-driven pharmaceutical company, we will benefit from
her experience in launching and marketing prescription medicines as we
increase patient and healthcare provider access to our flagship product
AMITIZA®, launch RESCULA® in the United States
later this year, and further develop our prostone-based pipeline to meet
the needs of millions of patients around the globe."
Silvia Taylor brings 20 years of marketing and communications experience
to Sucampo, including five years in public and media relations and 13
years in biopharmaceutical brand marketing at MedImmune and Pfizer Inc.
She has expertise in marketing, strategy, new product launches, social
media, direct-to-consumer advertising, communications, and public
health, and has held leadership roles for Viagra®, Exubera®,
motavizumab®, Synagis® and FluMist® as
well as other pre-launch products. Ms. Taylor joins Sucampo from
MedImmune where she held positions of increasing responsibility, among
them Senior Director of Marketing, RSV Franchise and Senior Director of
Marketing, Global Influenza Franchise. Prior to MedImmune, Ms. Taylor
worked at Pfizer from 1999 to 2007, where she worked on Viagra®
and Exubera® and in the company's consumer marketing
department on patient-directed communications. She is an expert in
engaging various healthcare-related audiences using a variety of
communications tools, from advertising to sales promotion to Facebook®.
Ms. Taylor's work has won numerous marketing and pharmaceutical industry
awards. She graduated from the University of Virginia with a B.A. in
Foreign Affairs and from Columbia Business School where she earned an
MBA in Marketing and Management.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc., a global pharmaceutical company, is
focused on the discovery, development, and commercialization of
proprietary drugs based on prostones.
The therapeutic potential of prostones, which occur naturally in the
human body as a result of enzymatic (15-PGDH) transformation of certain
fatty acids, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D.,
Sucampo Pharmaceuticals' Chairman and Chief Executive Officer. Dr. Ueno
founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno,
Ph.D., founding Chief Executive Officer and currently Advisor,
International Business Development, and a member of the Board of
Directors. For more information, please visit www.sucampo.com.
AMITIZA is a registered trademark of Sucampo Pharmaceuticals, Inc.
RESCULA is a registered trademark of R-Tech Ueno, Ltd., and has been
licensed to Sucampo. Viagra and Exubera are registered trademarks of
Pfizer Inc. Synagis, FluMist and motavizumab are registered trademarks
Sucampo Forward-Looking Statements
This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and involve
risks and uncertainties, which may cause results to differ materially
from those set forth in the statements. The forward-looking statements
may include statements regarding product development, product potential,
future financial and operating results, and other statements that are
not historical facts. The following factors, among others, could cause
actual results to differ from those set forth in the forward-looking
statements: the impact of pharmaceutical industry regulation and health
care legislation; Sucampo's ability to accurately predict future market
conditions; dependence on the effectiveness of Sucampo's patents and
other protections for innovative products; the risk of new and changing
regulation and health policies in the US and internationally and the
exposure to litigation and/or regulatory actions.
No forward-looking statement can be guaranteed and actual results may
differ materially from those projected. Sucampo undertakes no obligation
to publicly update any forward-looking statement, whether as a result of
new information, future events, or otherwise. Forward-looking statements
in this presentation should be evaluated together with the many
uncertainties that affect Sucampo's business, particularly those
mentioned in the risk factors and cautionary statements in Sucampo's
Form 10-K for the year ended Dec. 31, 2011, which the Company
incorporates by reference.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50326852&lang=en
Sucampo Pharmaceuticals, Inc.
Kate de Santis, +1-240-223-3834
© Business Wire 2012